Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
作者: Maubec EvePetrow PeterScheer-Senyarich IsabelleDuvillard PierreLacroix LudovicGelly JulienCertain AgnèsDuval XavierCrickx BéatriceBuffard ValérieBasset-Seguin NicoleSaez PierreDuval-Modeste Anne-BénédicteAdamski HenriMansard SandrineGrange FlorentDompmartin AnneFaivre SandrineMentré FranceAvril Marie-Françoise
作者单位: 1Hôpital Bichat, Service de Dermatologie, 46 rue Henri Huchard, Paris, cedex 75877, France. eve.maubec@bch.aphp.fr
刊名: Journal of Clinical Oncology, 2011, Vol.29 (25), pp.3419-26
来源数据库: PubMed Journal
DOI: 10.1200/JCO.2010.34.1735
原始语种摘要: To evaluate the efficacy and safety of cetuximab, a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), as a first-line monotherapy in patients with unresectable squamous cell carcinoma of the skin (SCCS).;;Thirty-six patients received cetuximab (initial dose of 400 mg/m(2) followed by subsequent weekly doses of 250 mg/m(2)) for at least 6 weeks with a 48-week follow-up. The primary end point was the disease control rate (DCR) at 6 weeks (according to Response Evaluation Criteria in Solid Tumors [RECIST] criteria). Secondary end points included best response rate, overall survival, progression-free survival (PFS), and toxicity assessment. Association of treatment efficacy with RAS mutations or FcγR genotypes was investigated.;;Median age of the study population...
全文获取路径: PubMed  (合作)
分享到:
来源刊物:
影响因子:18.038 (2012)

×
关键词翻译
关键词翻译
  • unresectable 不可切除的
  • squamous 具鳞的
  • carcinoma 癌症
  • survival 生存
  • SCCS Source Code Control System
  • monotherapy 硫化物
  • grade 品位
  • efficacy 效验
  • therapeutic 治疗的
  • serious 认真的